A Phase 2/3 interventional study of Dexmedetomidine and Placebo in Major Abdominal Surgery, Postoperative Delirium (POD) and Sleep Disturbances, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Not yet recruiting. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.
Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 10th largest by planned enrollment, is one of 16 that started in 2026, is one of 5 in phase 2/3, reaches primary completion later than 18 of the 31 other live ones, and was the 62nd registered.
753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.
Browse Emergence Delirium studies →31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:
Pakistan Institute of Medical Sciences · Sites in Pakistan
Ages 2–12 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 1–12
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Sites in Turkey
Ages 2–10
Bach Mai Hospital · Sites in Vietnam
Ages 18–65
Kasr El Aini Hospital · Sites in Egypt
Ages 2–6
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 65 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 13 · Phase 4 31
First in 2006; this study’s year is marked. 16 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 120 across 467 interventional studies indexed under Emergence Delirium.
Median enrollment 100 across the 83 interventional studies. Of the 38 that completed or were terminated, 10 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 83 have an industry lead sponsor. The 10 most frequent:
Sixth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 217 studies on the registry; 111 are open to participants now.
Sixth Affiliated Hospital, Sun Yat-sen University has 1 study filed under Emergence Delirium — fewer than ten, so there is no comparison to draw.
13 of the studies testing dexmedetomidine in Emergence Delirium that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07538284Phase 3Sixth Affiliated Hospital, Sun Yat-sen UniversityMInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES) | 2026-12-31 |
| NCT07810556Phase 3Assiut UniversityIntrathecal Dexmedetomidine and Postoperative Delirium in Elderly Hip Fracture Surgery | 2027-10 |
| NCT07519863Ain Shams UniversityThe Effect of Dormicum-Ketamine Versus Dexmedetomidine on Emergence Delirium During Deep Sedation in Paediatric Burn Patients | 2026-11 |
| NCT07799311Pakistan Institute of Medical SciencesComparing the Efficacy of Propofol and Dexmedetomidine in Prevention of Emergence Agitation After Sevoflurane Anesthesia in Children | 2026-11-28 |
| NCT07601698Sohag UniversityDexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 83 studies testing dexmedetomidine in Emergence Delirium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients.
Delirium is an acute, short-term brain dysfunction characterized by fluctuating consciousness, cognitive decline, inattention, and sleep-wake cycle disruption. Postoperative delirium (POD), occurring predominantly within the first postoperative week (especially days 3-5 in elderly patients), affects 11-45% of older adults after major surgery. POD prolongs hospitalization, increases morbidity and mortality 5,65,6, yet its pathophysiology remains unclear, and evidence-based pharmacological prevention is lacking. Thus, effective POD prevention strategies are urgently needed.
Preoperative anxiety, a modifiable risk factor for POD, affects 11-80% of surgical patients. It contributes to sleep disturbances (e.g., insomnia, early awakening), which may exacerbate POD via neuroendocrine and immune dysregulation. However, benzodiazepines (e.g., lorazepam, diazepam, midazolam), though effective anxiolytics, increase delirium risk and are contraindicated preoperatively per current guidelines.
Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist, induces physiological non-REM sleep without respiratory depression or hemodynamic instability. Its nasal formulation offers high bioavailability (82%), ease of administration, and is approved in China for preoperative sedation/anxiety. While intravenous (IV) DEX reduces POD in predominant ICU settings, its use in general wards remains unexplored. Preclinical studies suggest DEX enhances glymphatic clearance and exerts anti-inflammatory effects, potentially mitigating the development of POD. This study thus hypothesize that a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patient population. We set to demonstrate that to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in older patients undergoing major abdominal surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dexmedetomidine
Drug: Placebo
Intranasal dexmedetomidine (100 µg total: 4 sprays, 25 µg/spray; Hengrui Medicine, China) self-administered preoperatively (\~9 PM) and optionally on the night of surgery (patient decides dose: 0, 2 sprays, or 4 sprays).
Intranasal water for injection (4 sprays, identical volume as nasal dexmedetomidine; Hengrui Medicine, China) self-administered preoperatively (\~9 PM) and optionally on the night of surgery (patient decides dose: 0, 2 sprays, or 4 sprays).
Incidence of postoperative delirium
Confusion Assessment Method
Time frame: Up to postoperative day (POD) 7 or discharge (whichever first).
Delirium severity
Confusion Assessment Method Score
Time frame: Up to postoperative day (POD) 7 or discharge (whichever first)
Physical activity
Fitbit Flex2 tracker
Time frame: Up to postoperative day (POD) 3
Sleep quality
Fitbit Flex2 tracker and Athens Insomnia Scale
Time frame: Up to postoperative day (POD) 3
Anxiety
Hamilton Anxiety Scale
Time frame: Up to postoperative day (POD) 3
Pain intensity
Numerical Rating Scale
Time frame: Up to postoperative day (POD) 3
Opioid consumption
Intravenous morphine equivalents
Time frame: Up to postoperative day (POD) 3
Health related quality of life
Health related quality of life assessed with the SF-36 health survey
Time frame: On postoperative day (POD) 3 and 30
Quality of Recovery
The Quality of Recovery-15 questionnaire
Time frame: Up to postoperative day (POD) 3
Postoperative Nausea and Vomiting
Postoperative Nausea and Vomiting Scale
Time frame: Up to postoperative day (POD) 3
Post-anesthesia Care Unit (PACU) length of stay
Post-anesthesia Care Unit (PACU) length of stay
Time frame: Up to postoperative day (POD) 1
Optional intranasal administration on the night of surgery
Optional intranasal administration of the same spray (patient decides dose: 0, 2 sprays, or 4 sprays)
Time frame: At night of the surgery
Length of Hospital Stay
Medical Record Review
Time frame: From postoperative day 0 until date of hospital discharge (Up to 30 days)
Cognitive function
Abbreviated Mental Test Score
Time frame: Up to postoperative day (POD) 30
No study locations are listed for this record.
Plan to share: Yes — De-identified data and a data dictionary will be made available upon reasonable request to researchers who provide a methodologically sound proposal and whose use of the data has been approved the study authors. Data will be made available immediately following publication, with no anticipated end date, to achieve the aims specified in the approved proposal. Proposals should be directed to ruanxc@mail.sysu.edu.cn.
Supporting information: Study protocol, Informed consent form
Time frame: Immediately
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Sixth Affiliated Hospital, Sun Yat-sen University →